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INTRODUCTION 
Colorectal cancer, commonly known as bowel cancer, is a 
cancer caused by uncontrolled cell growth (neoplasia), in the 
colon, rectum, or vermiform appendix. Colorectal cancer is 
clin ically distinct from anal cancer, which affects the 
anus.Invasive cancers that are confined within the wall of the 
colon (TNM stages I and II) are often curable with surgery, For 
example, in England and Wales over 90% of patients 
diagnosed at this stage will survive the disease beyond 5 years. 
However, if left untreated, the cancer can spread to regional 
lymph nodes (stage III)  around 48% of patients diagnosed at 
this stage survive the disease beyond five years. Cancer that 
has spread widely around the body (s tage IV) is usually not 
curable approximately 7% of patients diagnosed at this stage 
survive beyond five years.
1
 Colorectal cancer is the third most 
commonly diagnosed cancer in the world, but it is more 
common in developed countries . More than half of the people 
who die of colorectal cancer live in a  developed region of the 
world. GLOBOCAN estimated that, in 2008, 1.23 million new 
cases of colorectal cancer were clin ically diagnosed, and that 
this type of cancer killed more than 600,000 people. 
2
 
Estimated new cases and deaths  from colon and rectal cancer 
in the United States in 2011 are- New cases: 101,340 (colon); 
39,870 (rectal) Deaths: 49,380 (co lon and rectal combined).
3
 
SYMPTOMS  
Local symptoms are more likely  if the tumor is located closer 
to the anus. There may be a change in bowel habit (such as 
unusual and unexplained constipation or diarrhea), and a 
feeling of incomplete defecation (rectal tenesmus). Lower 
gastrointestinal bleeding, including the passage of bright red 
blood in the stool, may indicate colorectal cancer, as may the 
increased presence of mucus. Melena, black stool with a tarry 
appearance, normally occurs in upper gastrointestinal bleeding 
(such as from a duodenal ulcer), but is sometimes encountered 
in colorectal cancer when the disease is located in the 
beginning of the large bowel.  
A tumor that is large enough to fill the entire lumen of the 
bowel may cause bowel obstruction. This situation is 
characterized by constipation, abdominal pain, and abdominal 
distension and vomiting. This occasionally leads to the 
obstructed and distended bowel perforat ing and causing 
peritonitis. A large left co lonic tumor may compress the left 
ureter and cause hydronephrosis.
4 
Certain local effects of colorectal cancer occur when the 
disease has become more advanced. A large tumor is more 
likely to be noticed on feeling the abdomen, and it may be 
noticed by a doctor on physical examination. The disease may 
invade other organs, and may cause blood or air in the urine 
(invasion of the bladder) or vaginal d ischarge (invasion of the 
female reproductive tract.   
Risk factors  
The lifet ime risk of developing colon cancer in the United 
States is about 7%. Certain factors increase a person's risk of 
developing the disease these includes: 
 Age: The risk of developing colorectal cancer increases 
with age. Most cases occur in the 60s and 70s.  
 Polyps of the colon, particularly adenomatous polyps, are 
a risk factor for colon cancer. The removal of colon 
polyps at the time of colonoscopy reduces the subsequent 
risk of colon cancer. 
 Heredity:  
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o Family h istory of colon cancer, especially in a close 
relative before the age of 55 or multiple relatives.  
o Familial adenomatous polyposis  (FAP) carries a near 
100% risk of developing colorectal cancer by the age 
of 40 if untreated 
o Hereditary nonpolyposis colorectal cancer (HNPCC) 
or Lynch syndrome 
o Gardner syndrome5 
 Smoking,: Smokers are more likely to die of colorectal 
cancer than nonsmokers. An American Cancer Society 
study found. Male s mokers had more than a 30% increase 
in risk of dying from the disease compared to men who 
never had smoked. 
6,7,8
 
 Diet : Studies show that a diet high in red meat and low in 
fresh fruit, vegetables, poultry and fish increases the risk 
of colorectal cancer. In June 2005, a study by the 
European Prospective Investigation into Cancer and 
Nutrit ion suggested that diets high in red and processed 
meat, as well as those low in fiber, are associated with an 
increased risk of colorectal cancer. Individuals who 
frequently eat fish showed a decreased risk. However, 
other studies have cast doubt on the claim that diets high 
in fiber decrease the risk of co lorectal cancer; rather, low-
fiber diet was associated with other risk factors, leading 
to confounding. The nature of the relationship between 
dietary fiber and risk of colorectal cancer remains 
controversia
 9
. 
 Lithocholic acid: Lithocholic acid is a bile acid that acts 
as a detergent to solubilize fats for absorption. It is made 
from chenodeoxycholic acid by bacterial action in the 
colon. It has been implicated in human and experimental 
animal carcinogenesis.  
 Viruses: Exposure to some viruses (such as particular 
strains of human papilloma virus) may be associated with 
colorectal cancer. 
 Primary sclerosing cholangitis  offers a risk independent 
to ulcerative colitis . 
 Low levels of selenium  
 Inflammatory bowel disease: About one percent of 
colorectal cancer patients have a history of chronic 
ulcerative colit is. Patients with colorectal Crohn's disease 
have a more than average risk of colorectal cancer, but 
less than that of patients with ulcerative co lit is.  
 Environmental factors. Industrialized countries are at a 
relatively increased risk compared to less developed 
countries that traditionally had high-fiber/ low-fat diets. 
Studies of migrant populations have revealed a role for 
environmental factors, particularly d ietary, in the etiology 
of colorectal cancers. 
 Exogenous hormones. The differences in the time trends 
in colorectal cancer in males and females could be 
explained by cohort effects in exposure to some gender-
specific risk factor; one possibility that has been 
suggested is exposure to estrogens. In contrast, there is 
evidence that exogenous estrogens such as hormone 
replacement therapy (HRT), Tamoxifen or oral 
contraceptives might be associated with colorectal 
tumors.  
 Alcohol: Drinking, especially heavily, may be a risk 
factor.  
 Vitamin B6 intake lowers the risk o f colorectal cancer.
11
  
Globally, cancer o f the colon and rectum is the third leading 
cause of cancer in males and the fourth leading cause of cancer 
in females. The frequency of colorectal cancer varies around 
the world. It is common in the Western world and is rare in 
Asia and Africa. In countries where the people have adopted 
western diets, the incidence of colorectal cancer is increasing.
12 
RECTAL CANCER: 
Rectal cancer occurs when cancerous cells develop in the 
tissue of the rectum. The rectum is the last part of the large 
intestine and leads to the anus, which is the opening to the 
outside of the body. Body waste is stored in the rectum until it 
is eliminated from the body through the anus. 
Although rectal cancer is a life -threatening disease, it is a 
highly curable fo rm of cancer if found early. Therefore, regular 
check-ups and screenings are very important.
13 
SIGN AND S YMPTOMS :
 14 
Common signs and symptoms of rectal cancer include:
 
o A change in bowel habits  
o Diarrhea, constipation, or feeling that the bowel does not 
empty completely  
o Blood, either bright red or very dark in the stool 
o Stools that are narrower than usual 
o General abdominal d iscomfort such as frequent gas pains, 
bloating, fullness or cramps 
o Weight loss with no known reason 
o Constant tiredness 
o Vomit ing 
WHAT IS CANCER OF THE COLON AND RECTUM?  
The colon is the part of the digestive system where the waste 
material is stored. The rectum is the end of the colon adjacent 
to the anus. Together, they form a long, muscular tube called 
the large intestine (also known as the large bowel). Tumors of 
the colon and rectum are growths arising from the inner wall of 
the large intestine. Ben ign tumors of the large intestine are 
called polyps. Malignant tumors of the large intestine are 
called cancers. Ben ign polyps do not invade nearby tissue or 
spread to other parts of the body. Benign polyps can be easily 
removed during colonoscopy and are not life-threatening. If 
benign polyps are not removed from the large intestine, they 
can become malignant (cancerous) over time. Most of the 
cancers of the large intestine are believed to have developed 
from polyps. Cancer of the colon and rectum (also referred to 
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as colorectal cancer) can invade and damage adjacent tissues 
and organs. Cancer cells can also break away and spread to 
other parts of the body (such as liver and lung) where new 
tumors form. The spread of colon cancer to distant organs is 
called metastasis of the colon cancer. Once metastasis has 
occurred in colorectal cancer, a complete cure o f the cancer is 
unlikely.    
Doctors are certain that colorectal cancer is not contagious (a 
person cannot catch the disease from a cancer patient). Some 
people are more likely to develop colorectal cancer than others. 
Factors that increase a person's risk of colorectal cancer 
include high fat intake, a family history of colorectal cancer 
and polyps, the presence of polyps in the large intestine, and 
chronic ulcerative co lit is.
15 
Diet and colon cancer 
Diets high in fat are believed to predispose humans to 
colorectal cancer. In countries with high colorectal cancer 
rates, the fat intake by the population is much higher than in 
countries with low cancer rates. It is believed that the 
breakdown products of fat metabolis m lead to the formation of 
cancer-causing chemicals (carcinogens). Diets high in 
vegetables and high-fiber foods such as whole-grain breads and 
cereals may rid the bowel of these carcinogens and help reduce 
the risk of cancer.
16 
Colon polyps and colon cancer  
Doctors believe that most colon cancers develop in colon 
polyps. Therefore, removing benign colon polyps can prevent 
colorectal cancer. Colon polyps develop when chromosome 
damage occurs in cells of the inner lining of the colon. 
Chromosomes contain genetic information inherited from each 
parent. Normally, healthy chromosomes control the growth of 
cells in an orderly manner. When chromosomes are damaged, 
cell growth becomes uncontrolled, resulting in masses of ext ra 
tissue (polyps). Colon polyps are initially benign. Over years, 
benign colon polyps can acquire additional chromosome 
damage to become cancerous.
17 
Ulcerative colitis and colon cancer  
  Chronic ulcerative colitis causes inflammation of the inner 
lin ing of the colon. For further information, please read the 
Ulcerative Colitis  article. Colon cancer is a recognized 
complication of chronic ulcerative colitis. 
18
The risk for cancer 
begins to rise after eight to 10 years of colit is. The risk of 
developing colon cancer in a patient with ulcerative colitis also 
is related to the location and the extent of his or her disease.
19 
Current estimates of the cumulative incidence of colon cancer 
associated with ulcerative colitis are 2.5% at 10 years, 7.6% at 
30 years, and 10.8% at 50 years. Patients at higher risk of 
cancer are those with a family history of colon cancer, a long 
duration of colit is, extensive colon involvement, and those with 
primary sclerosing cholangitis  (PSC).
20 
Genetics and colon cancer
21
 
A person's genetic background is an important factor in colon 
cancer risk. Among first-degree relat ives of colon cancer 
patients, the lifetime risk of developing colon cancer is 18% (a 
threefold increase over the general population in the United 
States). 
Even though family  history of colon cancer is an important risk 
factor, majority (80%) of co lon cancers occur sporadically in 
patients with no family history of colon cancer. Approximately 
20% of cancers are associated with a family history of colon 
cancer. And 5 % of colon cancers are due to hereditary colon 
cancer syndromes. Hereditary colon cancer syndromes are 
disorders where affected family members have inherited 
cancer-causing genetic defects from one or both of the parents. 
Chromosomes contain genetic informat ion, and chromosome 
damages cause genetic defects that lead to the formation of 
colon polyps and later colon cancer. In sporadic polyps and 
cancers (polyps and cancers that develop in the absence of 
family history), the chromosome damages are acquired 
(develop in a cell during adult life).
22
 The damaged 
chromosomes can only be found in the polyps and the cancers 
that develop from that cell. But in hereditary colon cancer 
syndromes, the chromosome defects are inherited at birth and 
are present in every cell in the body. Patients who have 
inherited the hereditary colon cancer syndrome genes are at 
risk of developing large number of colon polyps, usually at 
young ages, and are at very high risk of developing colon 
cancer early in life, and also are at  risk of developing cancers 
in other organs.
23 
HNPCC (hereditary nonpolyposis  colon cancer) is a hereditary 
colon cancer syndrome where affected family members can 
develop colon polyps and cancers, usually in the right colon, in 
their 30s to 40s. Certain HNPCC patients are also at ris k of 
developing uterine cancer, stomach cancer, ovarian cancer, and 
cancers of the ureters (the tubes that connect the kidneys to the 
bladder), and the biliary tract (the ducts that drain bile from the 
liver to the intestines). 
MYH polyposis syndrome is a recently discovered hereditary 
colon cancer syndrome. Affected members typically develop 
10-100 polyps occurring at around 40 years of age, and are at 
high risk o f developing colon cancer.
24 
SCREENING FOR COLORECTAL CANCER:  
Colorectal cancer (CRC) is preventable by removing 
pre‐cancerous lesions or adenomatous polyps long before 
invasive cancer develops. For the general population, screening 
is advised starting at age 50. 
 
Table.1. Stratification of CRC Risk Groups 
25
 
Risk Rating  Risk Criteria  
Average Risk  Age ≥ 50  
No personal history of adenoma, CRC 
or Inflammatory bowel disease Negative 
family history  
Increased Risk  Personal history of adenomas/sessile  
serrated polyps, CRC or inflammatory  
bowel disease Positive family history of 
CRC or advanced Adenomas  
High Risk  Family history of Lynch Syndrome  
Personal or family history of polyposis  
Syndromes  
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In this population, it is estimated that the risk of developing a 
colorectal adenoma is approximately 19% and that 2%‐5% of 
sporadic polyps will develop into an invasive carcinoma.1 5% 
to 15% of indiv iduals have a genetic predisposition for 
development of CRC, thus cancer can develop for these 
patients at an earlier age. Given that the risk of CRC is variant 
in indiv iduals based on high or average risk factors, 
recommendations for CRC screening are made accord ingly. 
25 
TES TS FOR CRC SCREENING
26
:  
 There are several options for CRC screening  
1. Fecal Occu lt Blood Testing (FOBT) detects blood loss in the 
stool. This test is performed on a fecal sample which has been 
placed on a guaiac‐impregnated card. Through addition of a 
hydrogen peroxide developer, a positive test is reflected in the 
appearance of a blue color. This test should be performed on 3 
separate bowel movements. Dietary substances like rare red 
meat, turnips or horseradish can result in a false positive or 
vitamin C can result in a false negative. Restrictions of these 
substances have not been shown to reduce this false positivity 
rate rather they may inhib it compliance with the testing. 
Additionally, it is recommended that non‐steroidal 
anti‐inflammatory drugs be avoided 7 days prior to testing as 
they can cause bleeding which can result in a false positive.
27
  
2. Fecal Immunohistochemical Test (FIT) was approved by the 
Food and Drug admin istration in 2001. It can detect hidden 
blood in the stool. It reacts to part of the human hemoglobin 
protein found in red blood cells. No d ietary restrictions are 
required prior to this test and it only requires one specimen.  
3. Stool DNA Test looks for certain abnormal sections of 
DNA. For this test an entire bowel movement is collected and 
examined in the lab for cancer cells. Time intervals for this test 
are not yet known.
28
  
4. Sigmoidoscopy is an invasive procedure using a 60 cm 
flexib le lighted tube inserted into the rectum and can visualize 
the lower part of the colon. A video camera is at the end of the 
scope and images are visualized on a display monitor. Polyps 
can be biopsied and removed through the scope. This 
procedure can be done without sedation.
29
 The greatest 
limitat ion of this procedure is that it can identify premalignant 
and malignant lesions in only half of the colon. Abnormal 
findings will result in the patient needing to undergo a 
colonoscopy.  
 
5. Colonoscopy is an invasive procedure through which the 
entire length of the colon is visualized through a colonoscope. 
Similar to the sigmoidoscope, it has a video camera on the end 
which allows the endoscopist to closely view the colon on a 
display screen. Biopsy and removal of suspicious findings can 
be done during the procedure. Patients typically receive 
anesthesia for this procedure.  
6. Double‐Contrast Barium Enema (DCBE) or lower 
gastrointestinal series. This procedure done in the radiology 
department entails the insertion of a small flexib le tube into the 
rectum through which barium is in jected. Air is injected 
following the barium to assist in expansion. DCBE is 
insensitive to detecting small or flat adenomas and is only 
recommended when a total colonoscopy cannot be completed.  
7. Computerized Tomography (CT) Colonoscopy or virtual 
colonoscopy uses 3‐dimensional imaging. During this test the 
patient will lie on a table and a small flexible tube is inserted 
into the rectum through which air is pumped in to expand the 
colon for better visualization. Positive findings on this test will 
require follow‐up with a colonoscopy. 3 Individuals ≥ 
50‐years‐old with no personal history of adenoma, CRC or 
inflammatory bowel disease or a family history of CRC are 
considered at average risk for developing colorectal cancer. 
Their lifetime risk for developing CRC is about 1 in 19 
(5.2%).
3
 
STAGE GROUPING  
TNM S TAGING S YS TEM
11
 
 The TNM Classification of Malignant Tumors (TNM) is a 
cancer staging system that    describes the extent of cancer in a 
patient’s body. 
  T describes the size of the tumors and whether it has 
invaded nearby tissue, 
 N describes regional lymph node that are involved, 
 M describes distant metastasis (spread of cancer from 
one body part to another). 
 The TNM staging system for all solid tumors was devised by 
Pierre Denoix between 1943 and 1952, using the size and 
extension of the primary tumor, its lymphatic   involvement, 
and the presence of metastases to classify the progression of 
cancer. 
TNM is developed and maintained by the International Union 
against Cancer (UICC) to achieve consensus on one globally 
recognized standard for classifying the extent of spread of 
cancer. The TNM classification is also used by the American 
Joint Committee on Cancer (AJCC) and the International 
Federation of Gynecology and Obstetrics (FIGO). 
31 
Most of the common tumors have their own TNM 
classification. Not all tumors have TNM classifications, e.g., 
there is no TNM classification for b rain tumors.  
The general outline for the TNM classificat ion is below. The 
values in parentheses give a range of what can be used for all 
cancer types, but not all cancers use this full range.
32 
Mandatory parameters ("T", "N", and "M")
 
 T: size or d irect extent of the primary tumor  
o Tx: tumor cannot be evaluated 
o Tis: carcinoma in situ 
o T0: no signs of tumor 
o T1, T2, T3, T4: size and/or extension of the primary 
tumor 
 N: degree of spread to regional lymph nodes  
o Nx: lymph nodes cannot be evaluated 
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o N0: tumor cells absent from reg ional lymph nodes 
o N1: regional lymph node metastasis present; (at 
some sites: tumor spread to closest or small number 
of regional lymph nodes) 
o N2: tumor spread to an extent between N1 and N3 
(N2 is not used at all sites) 
o N3: tumor spread to more d istant or numerous 
regional lymph nodes (N3 is not used at all sites) 
 M: presence of metastasis  
o Mx: distant metastasis cannot be evaluated 
o M0: no distant metastasis 
o M1: metastasis to distant organs (beyond regional 
lymph nodes) 
Once a person's T, N, and M categories have been determined, 
usually after surgery, this informat ion is combined in a process 
called stage grouping. The stage is expressed in Roman 
numerals from stage I (the least advanced) to stage IV (the 
most advanced). Some stages are subdivided with letters. 
33 
STAGES
 
Definition
11
 
Stage 0- Carcinoma in situ.Stage I, Stage II, and Stage III 
Higher numbers indicate more extensive disease indicate 
Larger tumor size and/or spread of the cancer beyond the organ 
in which it first developed to nearby lymph nodes and/or 
organs adjacent to the location of the primary tumor. Stage IV 
The cancer has spread to another organ(s).
34 
Stage 0  
Tis, N0, M0: The cancer is in the earliest stage. It has not 
grown beyond the inner layer (mucosa) of the colon or rectum. 
This stage is also known as carcinoma in situ or intramucosal 
carcinoma.  
Stage I  
T1-T2, N0, and M0: The cancer has grown through the 
muscularis mucosa into the submucosa (T1) or it may also 
have grown into the muscularis propria (T2). It has not spread 
to nearby lymph nodes or distant sites.  
Stage IIA  
T3, N0, M0: The cancer has grown into the outermost layers of 
the colon or rectum but has not gone through them (T3). It has 
not reached nearby organs. It has not yet spread to the nearby 
lymph nodes or distant sites.  
Stage IIB  
T4a, N0, and M0: The cancer has grown through the wall of 
the colon or rectum but has not grown into other nearby tissues 
or organs (T4a). It has not yet spread to the nearby lymph 
nodes or distant sites.  
Stage IIC  
T4b, N0, M0: The cancer has grown through the wall of the 
colon or rectum and is attached to or has grown into other 
nearby tissues or organs (T4b). It has not yet Spread to the 
nearby lymph nodes or distant sites.  
Stage IIIA  
One of the following applies.  
T1-T2, N1, and M0: The cancer has grown through the mucosa 
into the submucosa (T1) and it may also have grown into the 
muscularis propria (T2). It has spread to 1 to 3 nearby lymph 
nodes (N1a/N1b) or into areas of fat near the lymph nodes but 
not the nodes themselves (N1c). It has not spread to distant 
sites. 
Stage IIIB  
One of the following applies.  
T3-T4a, N1, and M0: The cancer has grown into the outermost 
layers of the colon or rectum (T3) or through the visceral 
peritoneum (T4a) but has not reached nearby organs. It has 
spread to 1 to 3 nearby lymph nodes (N1a/N1b) or into areas of 
fat near the lymph nodes but not the nodes themselves (N1c). It 
has not spread to distant sites. 
35 
T2-T3, N2a, and M0: The cancer has grown into the 
muscularis propria (T2) or into the outermost layers of the 
colon or rectum (T3). It has spread to 4 to 6 nearby lymph 
nodes (N2a). It has not spread to distant sites.  
T1-T2, N2b, and M0: The cancer has grown through the 
mucosa into the submucosa (T1) or it may also have grown 
into the muscularis propria (T2). It has spread to 7 or more 
nearby lymph nodes (N2b). It  has not spread to distant sites.  
Stage IIIC  
One of the following applies.  
T4a, N2a, and M0: The cancer has grown through the wall of 
the colon or rectum (including the visceral peritoneum) but has 
not reached nearby organs (T4a). It has spread to 4 to 6 nearby 
lymph nodes (N2a). It has not spread to distant sites.  
T3-T4a, N2b, and M0: The cancer has grown into the 
outermost layers of the colon or rectum (T3) or through the 
visceral peritoneum (T4a) but has not reached nearby organs. It 
has spread to 7 or more nearby lymph nodes (N2b). It has not 
spread to distant sites.  
T4b, N1-N2, and M0: The cancer has grown through the wall 
of the colon or rectum and is attached to or has grown into 
other nearby tissues or organs (T4b). It has spread to at least 
one nearby lymph node or into areas of fat near the lymph 
nodes (N1 or N2). It has not spread to distant sites.  
Stage IVA  
Any T, Any N, and M1a: The cancer may or may not have 
grown through the wall of the colon or rectum, and it may or 
may not have spread to nearby lymph nodes. It has spread to 1 
distant organ (such as the liver or lung) or set of lymph nodes 
(M1a).  
Stage IVB  
Any T, Any N, and M1b: The cancer may or may not have 
grown through the wall of the colon or rectum, and it may or 
Dilip et al                                           Journal of Drug Delivery & Therapeutics; 2012, 2(3): 60-66    65 
© 2011, JDDT. All Rights Reserved                                                           ISSN: 2250-1177                                                   CODEN: JDDTAO  
may not have spread to nearby lymph nodes. It has spread to 
more than 1 distant organ (such as the liver or lung) or set of 
lymph nodes, or it has spread to distant parts of the peritoneum 
(the lin ing of the abdominal cavity) (M1b).  
Prevention: 
Most colorectal cancers should be preventable, through 
increased surveillance, improved lifestyle, and, probably, the 
use of dietary chemo preventative agents. 
TERATMENT 
Treatment for rectal cancer may include surgery, chemotherapy 
or radiat ion therapy, or a combination of these approaches. 
Surgery is the main t reatment for all stages of rectal cancer, 
although radiation, chemotherapy, or both are often 
recommended in combination. Some patients who undergo 
surgery for rectal cancer require a permanent colostomy  a 
surgically created opening in the abdominal wall through 
which waste is excreted. 
36
 
THERAPIES FOR COLON AND RECTAL CANCER 
Combining Targeted Drugs Is Worse in Colorectal Cancer  
A clin ical trial testing chemotherapy combined with 
bevacizumab (Avastin) and cetuximab (Erbitux), and 
comparing this with chemotherapy and bevacizumab alone, 
found that the addition of cetuximab was actually worse for 
patients, according to the Feb. 5, 2009, New England Journal 
of Medicine. 
5-FU-Based Chemotherapy Cures Some Patients With 
Colon Cancer  
Researchers from the Adjuvant Colon Cancer Endpoints 
(ACCENT) Group used individual patient data from 18 phase 
III trials of adjuvant 5-FU-based chemotherapy for colon 
cancer to show that the regimens provide their survival benefit 
primarily by reducing the high risk of recurrence within the 
first two years after surgery, according to a study published 
online January 5, 2009, in the Journal of Clinical Oncology.
37
 
Colorectal Cancer Trials Support Gene Testing for Two 
Drugs  
A trio of 2008 studies adds to the growing evidence that 
patients with colorectal cancer should have their tumors tested 
for genetic mutations prior to starting therapy with cetuximab 
(Erbitux®) or panitumumab (Vectibix®).  
Related Treatment Information: 
Angiogenesis Inhibitors Therapy 
A fact sheet that describes the process of eliminating the blood 
supply to tumors. Lists the cancers in which this approach is 
being tested. 
Biological Therapies for Cancer 
A fact sheet that provides an overview of how the immune 
system functions and describes the actions of biological 
therapies. 
Radiation Therapy for Cancer 
A fact sheet that defines the different types of radiation therapy 
and discusses scientific advances that improve the 
effectiveness of this treatment. 
Targeted Cancer Therapies 
This NCI fact sheet describes targeted cancer therapies, which 
are drugs that block the growth and spread of cancer by 
interfering with specific molecules involved in carcinogenesis 
(the process by which normal cells are transformed into cancer 
cells) and tumor growth. 
Chemotherapy 
Chemotherapy is used to reduce the likelihood of metastasis 
developing, shrink tumor size, or slow tumor growth. 
Chemotherapy is often applied after surgery (adjuvant), before 
surgery (neoadjuvant), or as the primary therapy (palliative). 
The treatments listed here have been shown in clinical trials to 
improve survival and/or reduce mortality rate, and have been 
approved for use by the US Food and Drug Administration. In 
colon cancer, chemotherapy after surgery is usually only given 
if the cancer has spread to the lymph nodes(Stage III).  
 Adjuvant (after surgery) chemotherapy  
o 5-Fluorouracil(5-FU) or Capecitabine (Xeloda) 
o Lucovorine(LV, folinic Acid) 
 Chemotherapy for metastatic disease. Commonly used 
first line regimens involve the combination of infusional 
5-fluorouracil,leucovorine and oxaliplat in Oxaliplat in 
(FOLFOX) with bevacizumab or infusional 5-
fluorouracil, leucovorin, and irinotecan (FOLFIRI) with 
bevacizumab or the same chemotherapy drug 
combinations with cetuximab in KRAS wild type 
tumors.
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o 5-fluorouracil (5-FU) 
o capecitabine (Xeloda) 
o UFT or Tegafur-uracil 
o Leucovorin (LV, fo lin ic Acid) 
o Irinotecan (Camptosar) 
o Oxaliplatin (Eloxatin) 
o Gemcitabine (Gemzar) 
o Bevacizumab (Avastin) 
o Cetuximab (Erbitux) 
o Panitumumab (Vect ibix) 
 In clinical trials for treated/untreated metastatic disease.39  
o Bortezomib (Velcade) 
o Oblimersen (Genasense, G3139) 
o Gefitinib and erlotin ib (Tarceva) 
o Topotecan (Hycamtin) 
At the 2008 annual meeting of the American Society of 
Clin ical Oncology, researchers announced that colorectal 
cancer patients that have a mutation in the KRAS gene do not 
respond to certain therapies, those that inhibit the epidermal 
growth factor receptor (EGFR)--namely Erb itux (cetuximab) 
and Vect ibix (panitumumab).
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 Following recommendations by 
ASCO, patients should now be tested for the KRAS gene 
mutation before being offered these EGFR-inhib iting drugs. In 
July 2009, the US Food and Drug Administration (FDA) 
updated the labels of two anti-EGFR monoclonal antibody 
drugs (panitumumab (Vectib ix) and cetuximab (Erb itux)) 
indicated for treatment of metastatic colorectal cancer to 
include information about KRAS mutations.
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CONCLUS ION  
We can conclude the matter given in this review as colorectal 
cancer (CRC) is a second largest type of cancer in developed 
countries, as data of 2011, 49,380 death and approx 1,40,000 
patients were reported as new case of colorectal cancer in 
America. CRC is start with a tumor  in lower part of co lon or 
in rectum part in itially it change the bowel habits. Factors 
affecting CRC are age (60-70 years), hered ity, smoking, d iet 
alcohol etc. it can be prevent by removing pre‐cancerous 
lesions or adenomatous polyps before invasive cancer 
develops, screening of crc can be done by some test like 
FBOT, FIT, STOOL DNA, colonoscopy, DCBE, CT etc. Stage 
of cancer can be identify by TNM staging system and it can be 
treat by surgery, chemotherapy or radiation therapy, or a 
combination of these approaches. Chemotherapy is often 
applied after surgery (adjuvant), and before surgery 
(neoadjuvant), or as the primary therapy (palliative). 5-
fluorouracil (5-FU),capecitabine (Xeloda) etc are the drugs 
used for chemotherapyof CRC. 
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